Laura Kiessling
@ChemicalBiology
MIT Prof Chem and Founding Editor of ACS Chemical Biology (she/her)
ID:18871354
http://pubs.acs.org/journal/acbcct 11-01-2009 16:33:00
5,9K Tweets
20,9K Followers
2,0K Following
Just heard a beautiful presentation on this research from Meilin Zhu in Blainey Lab and Doug Kwon suggesting that lipid metabolism can be exploited to promote the growth of species that suppress bacterial vaginosis #WomensHealth
It's happening again! The 8th New England Glycochemistry Meeting - Sat. June 8, 2024 at Brandeis! #glycotime with @StaceyMalaker Herzon Lab Christopher Reid Linda Hsieh-Wilson Carole Bewley NIDDK
& 🫵! Sign up at –
negcmu.sites.northeastern.edu
First pre-print from the lab!
“Carbohydrate-active enzymes from Akkermansia muciniphila breakdown mucin O-glycans to completion”
🌟Cassie Bakshani Taiwo Ojuri 🌟
IMIBirmingham #glycotime we hope people enjoy reading it!
biorxiv.org/content/10.110…
I’m looking forward to seeing all of the new creative work that comes out of your group. We Kiessling Group congratulate you!
Thrilled that #ACSSpring2024 Council voted to approve BIOL ACS Biological ChemBio and Chemical Biochem 's name change request to *Biochemistry and Chemical Biology*! 90% of BIOL members voted that this better represents them & we hope to provide a home for even more scientists
American Chemical Society - More soon!
A fascinating read and thread that highlights an unexpected interplay of antibiotics and mucus secretion. And since mucus is made of highly glycosylated proteins, tagging this excellent thread #glycotime
Headed to New Orleans for #ACSSpring2024 ? Be sure to catch presentations from our group: Valerie will be presenting on Sunday at 3:55 PM and Victoria Marando and Laura Kiessling on Tuesday at 12:55 and 2:10 PM
I had so much fun talking with Alex Moloney (back of the napkin podcast) about chemical biology, research, and the upcoming Women in CARB symposium ACS_CARB at the American Chemical Society meeting. The @ACS_CARB lineup has some cool glycoscience! #glycotime
tinyurl.com/455ze5s6
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
Nature Medicine
rdcu.be/dzUlx